Core Insights - Zhengye Biological (ZYBT) experienced a 3.67% increase in stock price, reaching $5.65 per share with a total market capitalization of $26.8 million as of August 7 [1] - The company's total revenue for the year ending December 31, 2024, is projected to be 186 million RMB, reflecting a year-on-year decrease of 11.95% [1] - The net profit attributable to the parent company is expected to be 11.31 million RMB, showing a significant decline of 64.04% year-on-year [1] Company Overview - Zhengye Biological Holdings Limited is a Cayman Islands-registered holding company that operates primarily through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1] - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1]
正业生物上涨3.67%，报5.65美元/股，总市值2.68亿美元